Vulvovaginal candidiasis risk during standard anti-tuberculosis therapy
Fungal overgrowth causing vulvovaginal candidiasis can occur during systemic antibiotic exposure because antibiotics can disrupt normal vaginal microbiota and increase Candida risk [1,2]. Standard anti-tuberculosis regimens are not categorically listed as a direct cause of vulvovaginal candidiasis, but candidiasis risk can rise during treatment because systemic therapy can change the host environment and vaginal microbial balance [1,2,3].
Mechanisms supporting a plausible link
Candida overgrowth can follow changes in the body’s natural environment, including antibiotic exposure [1]. Systemic antibiotics are recognized risk factors for yeast (Candida) vaginitis because normal protective vaginal bacteria can be reduced [2].
Clinical timing considerations
New symptomatic vulvovaginal candidiasis can present during periods of disrupted host-microbiome balance after antibiotic exposure, including during the first weeks of systemic therapy [1,2].
Differential diagnosis for vaginal pruritus in the first month of therapy
Vaginal pruritus during treatment requires evaluation for common causes of vaginitis, including bacterial vaginosis and trichomoniasis, because symptoms overlap with yeast infection [4]. Diagnostic confirmation of Candida via microscopy or testing is recommended when symptoms are atypical, recurrent, or when empiric therapy fails [5].
Key evaluation and testing steps
Vaginal pH testing and microscopy (wet mount or equivalent) are used to support the diagnosis of vulvovaginal candidiasis and to exclude non-Candida causes of vaginitis [5]. Vaginal fungal culture or approved diagnostic testing is indicated when recurrent disease or non-albicans species is suspected or when clinical response is poor [5].
Management implications
If vulvovaginal candidiasis is confirmed, guideline-based antifungal therapy is recommended for symptom relief and eradication of Candida [5]. If symptoms do not respond to appropriate antifungal therapy, reassessment for alternative diagnoses is recommended [5].
Common misattributions
Vaginal fungal infection should not be assumed solely because anti-tuberculosis therapy was started, because vaginal pruritus commonly has non-fungal causes that can be triggered or unmasked during therapy [4,5].
Practical clinical conclusion
Vulvovaginal candidiasis can occur during the first month of treatment because systemic antibiotics can increase the risk of Candida overgrowth [1,2]. Direct causality from specific anti-tuberculosis drugs is not established as a universal effect, so confirmation of candidiasis versus other vaginitis etiologies is clinically necessary [4,5].